Sicard Flavie, Contesse Vincent, Lefebvre Hervé, Ait-Ali Djida, Gras Marjorie, Cartier Dorthe, Decker Annick, Chartrel Nicolas, Anouar Youssef, Vaudry Hubert, Delarue Catherine
INSERM Unité 413, European Institute for Peptide Research (Institut Fédératif de Recherches Multidisciplinaires sur les Peptides 23), Laboratory of Cellular and Molecular Neuroendocrinology, University of Rouen, 76821 Mont-Saint-Aignan, France.
J Clin Endocrinol Metab. 2006 Aug;91(8):3131-7. doi: 10.1210/jc.2006-0105. Epub 2006 May 16.
Neurotensin (NT) modulates corticosteroid secretion from the mammalian adrenal gland.
The objective of this study was to investigate the possible involvement of NT in the control of cortisol secretion in the human adrenal gland.
In vitro studies were conducted on cultured human adrenocortical cells.
This study was conducted in a university research laboratory.
Adrenal explants from patients undergoing expanded nephrectomy for kidney cancer were studied.
Cortisol secretion from cultured adrenocortical cells was measured.
NT1-11, the N-terminal fragment of NT, dose-dependently inhibited basal and ACTH-stimulated cortisol production by human adrenocortical cells in primary culture. In contrast, NT had no influence on cortisol output at concentrations up to 10(-6) m. HPLC and RT-PCR analyses failed to detect any significant amounts of NT and NT mRNA, respectively, in adrenal extracts. Molecular and pharmacological studies were performed to determine the type of NT receptor involved in the corticostatic effect of NT1-11. RT-PCR analysis revealed the expression of NT receptor type (NTR) 3 mRNA but not NTR1 and NTR2 mRNAs in the human adrenal tissue. However, the pharmacological profile of the adrenal NT1-11 receptor was different from that of NTR3, indicating that this receptor type is not involved in the action of NT1-11 on corticosteroidogenesis.
Our results indicate that NT1-11 may act as an endocrine factor to inhibit cortisol secretion through activation of a receptor distinct from the classical NTR1, NTR2, and NTR3.
神经降压素(NT)可调节哺乳动物肾上腺皮质激素的分泌。
本研究旨在探讨NT是否参与人类肾上腺皮质醇分泌的调控。
对培养的人肾上腺皮质细胞进行体外研究。
本研究在大学研究实验室进行。
对因肾癌接受扩大性肾切除术患者的肾上腺组织进行研究。
测定培养的肾上腺皮质细胞的皮质醇分泌。
NT的N端片段NT1-11可剂量依赖性抑制原代培养的人肾上腺皮质细胞基础状态及促肾上腺皮质激素(ACTH)刺激状态下的皮质醇生成。相比之下,浓度高达10⁻⁶ m的NT对皮质醇分泌无影响。高效液相色谱(HPLC)和逆转录-聚合酶链反应(RT-PCR)分析分别未能在肾上腺提取物中检测到任何显著量的NT及NT mRNA。进行分子和药理学研究以确定参与NT1-11皮质醇分泌抑制作用的NT受体类型。RT-PCR分析显示人肾上腺组织中存在NT受体3型(NTR3)mRNA的表达,但不存在NTR1和NTR2 mRNA的表达。然而,肾上腺NT1-11受体的药理学特征与NTR3不同,表明该受体类型不参与NT1-11对皮质醇生成的作用。
我们的结果表明,NT1-11可能作为一种内分泌因子,通过激活一种不同于经典NTR1、NTR2和NTR3的受体来抑制皮质醇分泌。